SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by J. Goldman & Co LP

J. Goldman & Co LP cut its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 15.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,503 shares of the company's stock after selling 9,733 shares during the quarter. J. Goldman & Co LP owned about 0.07% of SpringWorks Therapeutics worth $1,933,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Huntington National Bank increased its position in shares of SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after purchasing an additional 192 shares during the last quarter. AlphaQuest LLC boosted its stake in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after buying an additional 414 shares during the period. Venturi Wealth Management LLC purchased a new position in shares of SpringWorks Therapeutics in the 4th quarter valued at about $45,000. KBC Group NV boosted its stake in shares of SpringWorks Therapeutics by 59.1% in the 4th quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after buying an additional 978 shares during the period. Finally, US Bancorp DE boosted its stake in shares of SpringWorks Therapeutics by 56.0% in the 4th quarter. US Bancorp DE now owns 4,336 shares of the company's stock valued at $157,000 after buying an additional 1,556 shares during the period.

Insider Activity at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, insider Bhavesh Ashar sold 1,016 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the transaction, the insider now directly owns 62,053 shares of the company's stock, valued at $3,797,023.07. This represents a 1.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Saqib Islam sold 10,672 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $59.92, for a total value of $639,466.24. Following the completion of the transaction, the chief executive officer now directly owns 1,063,953 shares in the company, valued at approximately $63,752,063.76. The trade was a 0.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 158,016 shares of company stock worth $9,102,946. 7.83% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on SWTX shares. Cowen lowered SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday, April 29th. TD Cowen reissued a "hold" rating and issued a $47.00 target price (down previously from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Barclays reissued an "equal weight" rating and issued a $47.00 target price (down previously from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Guggenheim reaffirmed a "neutral" rating and set a $47.00 price objective on shares of SpringWorks Therapeutics in a research note on Monday. Finally, Evercore ISI lowered SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, SpringWorks Therapeutics has an average rating of "Hold" and a consensus target price of $52.57.

SpringWorks Therapeutics Stock Performance

Shares of NASDAQ:SWTX traded down $0.14 during mid-day trading on Thursday, hitting $46.08. 5,031,309 shares of the company traded hands, compared to its average volume of 2,067,086. The firm has a market cap of $3.46 billion, a P/E ratio of -13.24 and a beta of 0.77. SpringWorks Therapeutics, Inc. has a 52-week low of $28.21 and a 52-week high of $62.00. The firm's 50 day simple moving average is $44.10 and its 200 day simple moving average is $41.94.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.30). The company had revenue of $49.09 million for the quarter, compared to analysts' expectations of $64.19 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. Equities research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.